A tumor-targeted nanoplatform with stimuli-responsive cascaded activities for multiple model tumor therapy

2020 ◽  
Vol 8 (7) ◽  
pp. 1865-1874 ◽  
Author(s):  
Ronghua Jin ◽  
Jirong Xie ◽  
Xiaoshan Yang ◽  
Yu Tian ◽  
Pingyun Yuan ◽  
...  

A rambutan-like nanocomplex was designed to achieve low-drug-efflux chemotherapy and low-temperature photothermal therapy for effective and accurate tumor treatment.

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Wei Cao ◽  
Mengyao Jin ◽  
Kang Yang ◽  
Bo Chen ◽  
Maoming Xiong ◽  
...  

AbstractChemodynamic therapy (CDT) catalyzed by transition metal and starvation therapy catalyzed by intracellular metabolite oxidases are both classic tumor treatments based on nanocatalysts. CDT monotherapy has limitations including low catalytic efficiency of metal ions and insufficient endogenous hydrogen peroxide (H2O2). Also, single starvation therapy shows limited ability on resisting tumors. The “metal-oxidase” cascade catalytic system is to introduce intracellular metabolite oxidases into the metal-based nanoplatform, which perfectly solves the shortcomings of the above-mentioned monotherapiesIn this system, oxidases can not only consume tumor nutrients to produce a “starvation effect”, but also provide CDT with sufficient H2O2 and a suitable acidic environment, which further promote synergy between CDT and starvation therapy, leading to enhanced antitumor effects. More importantly, the “metal-oxidase” system can be combined with other antitumor therapies (such as photothermal therapy, hypoxia-activated drug therapy, chemotherapy, and immunotherapy) to maximize their antitumor effects. In addition, both metal-based nanoparticles and oxidases can activate tumor immunity through multiple pathways, so the combination of the “metal-oxidase” system with immunotherapy has a powerful synergistic effect. This article firstly introduced the metals which induce CDT and the oxidases which induce starvation therapy and then described the “metal-oxidase” cascade catalytic system in detail. Moreover, we highlight the application of the “metal-oxidase” system in combination with numerous antitumor therapies, especially in combination with immunotherapy, expecting to provide new ideas for tumor treatment.


2020 ◽  
Vol 21 ◽  
pp. 100883
Author(s):  
Ronghua Jin ◽  
Qiao Wang ◽  
Geng Dou ◽  
Yongkang Bai ◽  
Shiyu Liu ◽  
...  

2019 ◽  
Vol 8 (2) ◽  
Author(s):  
Shingo Nishikawa ◽  
Ryo Ariyasu ◽  
Tomoaki Sonoda ◽  
Masafumi Saiki ◽  
Takahiro Yoshizawa ◽  
...  

A 27-year-old man was diagnosed with inflammatory myofibroblastic tumor, and multiple lymph node and subcutaneous metastases. After several administrations of anti-tumor therapy, he underwent mediastinal lymph node biopsy using endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) to confirm tumor relapse. Five weeks later, he complained of chest pain, then rapidly developed shock due to acute pericarditis. Although he was treated with antibiotics for anaerobic bacterial infection and cardiac drainage, mediastinal lymph node abscess and pericarditis did not improve. After the surgical procedure, his physical condition dramatically improved and he was treated with another molecularly targeted therapy. Pericarditis associated with EBUS-TBNA is extremely rare. In this case, salvage was achieved by surgical drainage of the lymph node abscess and pericarditis, and long survival was obtained with further administration of anti-tumor treatment.


2018 ◽  
Vol 18 (10) ◽  
pp. 945-956 ◽  
Author(s):  
Mengting Ou ◽  
Shun Li ◽  
Liling Tang

PRDM14 belongs to the PR domain-containing (PRDM) family. Although a precise understanding focused on the function of PRDM14 to maintain stemness and pluripotency in embryonic stem cells via epigenetic mechanisms, growing experimental evidence has been linked PRDM14 to human cancers. In adults, PRDM14 has low expression in human tissues. Aberrant PRDM14 expression is connected with various malignant histological types and solid cancers, where PRDM14 can act as a driver of oncogenic processes. Overexpression of RPDM14 enhanced cancer cells growth and reduced cancer cells sensitive to chemotherapeutic agents. Reducing the expression of PRDM14 in cancer cells can enhance the therapeutic sensitivity of drugs to cancer cells, suggesting that aberrant PRDM14 may have a carcinogenic characteristic in tumor therapy and as a new molecular target. This review summarizes the structure and oncogenic properties of PRDM14 in different malignancies and suggests that PRDM14 may be a potential therapeutic molecular target for tumor treatment.


Author(s):  
Claudia de Wall ◽  
Johann Bauersachs ◽  
Dominik Berliner

AbstractModern treatment strategies have improved prognosis and survival of patients with malignant diseases. The key components of tumor treatment are conventional chemotherapy, radiotherapy, targeted therapies, and immunotherapy. Cardiovascular side-effects may occur in the early phase of tumor therapy or even decades later. Therefore, knowledge and awareness of acute and long-lasting cardiac side effects of anti-cancer therapies are essential. Cardiotoxicity impairs quality of life and overall survival. The new cardiologic subspecialty ‘cardio-oncology’ deals with the different cardiovascular problems arising from tumor treatment and the relationship between cancer and heart diseases. Early detection and treatment of cardiotoxicity is of crucial importance. A detailed cardiac assessment of patients prior to administration of cardiotoxic agents, during and after treatment should be performed in all patients. The current review focusses on acute and long-term cardiotoxic side effects of classical cytotoxic and selected modern drug treatments such as immune checkpoint inhibitors and discusses strategies for the diagnosis of treatment-related adverse cardiovascular effects in cancer patients.


Author(s):  
Endong Zhang ◽  
Zicheng Zuo ◽  
Wen Yu ◽  
Hao Zhao ◽  
Shengpeng Xia ◽  
...  

Carbon monoxide (CO) gas therapy has grown to be an emerging tumor therapy strategy to avoid low treatment efficiency of photodynamic therapy (PDT) caused by the hypoxia tumor microenvironment. However,...


2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Xiaoxia Song ◽  
Zhi Chen ◽  
Xue Zhang ◽  
Junfeng Xiong ◽  
Teng Jiang ◽  
...  

AbstractMagnetic micro/nanorobots attracted much attention in biomedical fields because of their precise movement, manipulation, and targeting abilities. However, there is a lack of research on intelligent micro/nanorobots with stimuli-responsive drug delivery mechanisms for cancer therapy. To address this issue, we developed a type of strong covalently bound tri-bead drug delivery microrobots with NIR photothermal response azobenzene molecules attached to their carboxylic surface groups. The tri-bead microrobots are magnetic and showed good cytocompatibility even when their concentration is up to 200 µg/mL. In vitro photothermal experiments demonstrated fast NIR-responsive photothermal property; the microrobots were heated to 50 °C in 4 min, which triggered a significant increase in drug release. Motion control of the microrobots inside a microchannel demonstrated the feasibility of targeted therapy on tumor cells. Finally, experiments with lung cancer cells demonstrated the effectiveness of targeted chemo-photothermal therapy and were validated by cell viability assays. These results indicated that tri-bead microrobots have excellent potential for targeted chemo-photothermal therapy for lung cancer cell treatment.


2021 ◽  
Author(s):  
Dan Peng ◽  
Genhua Liu ◽  
Ye He ◽  
Pengfei Gao ◽  
Shuangquan Gou ◽  
...  

Recently, photothermal therapy (PTT) has been recognized as a viable alternative strategy against bacterial biofilm infection. However, hyperthermia required for PTT to ablate biofilm usually induced damage of normal tissue/organ...


2021 ◽  
Author(s):  
Moataz Dowaidar

Customized nanomedicines can be used in a variety of ways, including angiogenesis suppression, vascular disruption, and vascular infarction. In the angiogenesis suppression approach, VEGF, VEGFR, mTOR, EGFR, bFGF, ROS, and other components have become promising therapeutic targets. The nanomedicine system has successfully inhibited tumor neovascularization using gene silencing, chemotherapy, photothermal therapy, and other therapies. In the vascular disruption approach, VDAs supplied by nanomaterials were bonded with the bonding sites of CA4, COL, PTX, and other medications on microtubules to promote rapid disintegration of tumor vascular wall cells. Combining many medicines increased the tumor treatment outcome even more. For example, disruption of tumor blood arteries caused by nanoparticle-mediated physical methods combined with chemotherapy resulted in effective treatment in a large volume tumor model. The vascular infarction methodology uses a variety of carriers, including nanoparticles, DNA nanorobots, platelet membranes, and others, to carry thrombin, tTF, and other drugs to generate local thrombosis and provide safe and effective tumor treatment.


Sign in / Sign up

Export Citation Format

Share Document